Eli Lilly’s oral weight-loss pill shakes Novo Nordisk as investors brace for market shift
Novo Nordisk shares drop after Eli Lilly’s oral weight-loss pill shows promise. Analysts see a shifting obesity drug market. What this means for investors. Read More
Novo Nordisk’s Mim8 shows promising efficacy and safety in haemophilia A children, phase 3 interim results reveal
Novo Nordisk A/S has announced encouraging interim results from its phase 3 FRONTIER3 clinical trial, highlighting the potential of its investigational drug, Mim8, as a ... Read More
Novo Nordisk’s Amycretin outshines rivals in weight-loss drug trials
Novo Nordisk has achieved a critical milestone in the fight against obesity, reporting highly promising results from an early-stage clinical trial of its weight-loss drug, ... Read More
Novo Nordisk’s semaglutide 7.2 mg sets new standard in obesity treatment with STEP UP trial results
Novo Nordisk, a leader in chronic disease care, has unveiled compelling results from its STEP UP obesity trial. This global, phase 3b clinical study, part ... Read More
Novo Nordisk and Valo Health expand AI partnership to tackle cardiometabolic diseases
Novo Nordisk and Valo Health have strengthened their collaboration to advance AI-driven drug discovery, targeting major cardiometabolic diseases, including obesity, type 2 diabetes, and cardiovascular ... Read More
Novo Nordisk’s CagriSema demonstrates superior weight loss results in REDEFINE 1 trial
Novo Nordisk A/S has unveiled significant findings from its REDEFINE 1 trial, marking a major advancement in the treatment of obesity and overweight conditions. Conducted ... Read More
Novo Nordisk set to finalize $11bn acquisition of Catalent manufacturing sites
Novo Nordisk is set to finalise its acquisition of three Catalent manufacturing sites, marking a pivotal step in its strategy to bolster global manufacturing capabilities ... Read More
Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors
Hims & Hers Health Inc. saw its stock surge following a robust quarterly earnings report, which showcased significant growth in revenue and subscriber numbers. Despite ... Read More
Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has ... Read More
Setback for diabetes innovation: FDA puts brakes on Novo Nordisk’s once-weekly insulin icodec
Novo Nordisk announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application for its ... Read More